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HIGHLIGHTS
 SARS-CoV-2, the virus that causes COVID-19, is a novel CoV that infects humans by binding to ACE2, which degrades
angiotensin II, and hence plays a critical role in modulating the renin angiotensin system (RAS).
 The emerging epidemiology of COVID-19 suggests that patients with cardiovascular risk factors, including older age,
cardiovascular disease, or cancer may be more susceptible to infection and suffer from worse clinical outcomes.
 Because of the limited understanding with respect to the interaction of RAS inhibitors and SARS-CoV-2 infectivity, we
endorse current society recommendations to continue RAS antagonists for clinical indications for which these agents are
known to be beneficial.
 Treatments for COVID-19 that are undergoing clinical trials range from therapies that block the entry of SARS-CoV-2 into
host cells, to repurposed antiviral therapies such as protease inhibitors and nucleoside analogs that block viral replication
by inhibiting viral RNA-dependent RNA polymerase.
SUMMARY
The coronavirus disease-2019 (COVID-19) pandemic has resulted in a proliferation of clinical trials designed to slow the
spread of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). Many therapeutic agents that are being used
to treat patients with COVID-19 are repurposed treatments for influenza, Ebola, or for malaria that were developed
decades ago and are unlikely to be familiar to the cardiovascular and cardio-oncology communities. Here, the authors
provide a foundation for cardiovascular and cardio-oncology physicians on the front line providing care to patients with
COVID-19, so that they may better understand the emerging cardiovascular epidemiology and the biological rationale for
the clinical trials that are ongoing for the treatment of patients with COVID-19. (J Am Coll Cardiol Basic Trans Science
2020;5:501–17) © 2020 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.
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T he coronavirus disease-2019(COVID-19) pandemic has resultedin a proliferation of clinical trials
that are designed to slow the spread of
severe acute respiratory syndrome-
coronavirus-2 (SARS-CoV-2), the virus that
causes COVID-19. These therapies range from
vaccines, to repurposed treatments for influ-
enza, to drugs that were not effective in pa-
tients with Ebola, to treatments for malaria
that were developed decades ago. Recog-
nizing that patients with underlying cardio-
vascular risk factors, cardiovascular disease,
or cancer have an increased risk for adverse
outcomes with COVID-19, and recognizing
that these vulnerable populations may be
enrolled in COVID-19 clinical trials, here we
present a critical review of the rationale for
the different therapeutics that are currently
being employed. As background, we first re-
view the epidemiology of COVID-19, followed
by the biology of CoV. We then briefly define
the complex interplay between the CoV and
the renin-angiotensin system (RAS), which
is directly relevant to the care of the
majority of patients with cardiovascular
disease or cancer who are receiving drugs
that modulate this system. Finally, we review the
mechanisms of action of the multiple therapies that
are currently being studied in clinical trials. Given
the breadth of information that is emerging, we will
not discuss the role of vaccines.
EPIDEMIOLOGY OF COVID-19
The current impact of the novel CoV, SARS-CoV-2 is
unquantifiable. The number of confirmed cases and
deaths from the global COVID-19 pandemic increase
daily (1,2). Although there is a great deal that still
remains to be understood, initial reports from 552
hospitals in China describing 1,099 of the 7,736 pa-
tients infected with COVID-19 provide some insight
into the disease (3). In this multicenter retrospective
analysis, the majority were Wuhan residents or had
contact with Wuhan residents, although 25.9% were
neither. The median age of patients was 47 years
(interquartile range [IQR]: 35 to 58 years), and 41.9%
were female. Patients with more severe disease,
compared with those with nonsevere disease, tended
to be older and tended to suffer from at least 1 co-
morbidity. In this retrospective analysis, patients
commonly received intravenous antibiotics (58.0%).
Oseltamivir was administered in 35.8%, systemic
steroids in 18.6%, and oxygen in 41.3% of patients.
The median duration of hospitalization was 12.0 days
(IQR: 10.0 to 14.0 days); however, the majority of the
patients (93.6%) remained hospitalized at the time of
data analysis and as such, the clinical course still
largely remains to be defined.
COVID-19 AND CARDIOVASCULAR COMPLICATIONS.
Epidemiologic data thus far suggest that patients with
cardiovascular risk factors, including older age, car-
diovascular disease, or cancer are more susceptible to
infection and suffer from worse clinical outcomes (4).
COVID-19 can also directly result in a number of car-
diovascular complications, including fulminant
myocarditis, myocardial injury, heart failure, and
arrhythmia (3,5,6). There have been a number of
published case reports of clinically suspected
myocarditis as suggested by: markedly elevated
troponin levels, ST-segment elevation on electrocar-
diogram without obstructive coronary disease,
severely decreased left ventricular systolic function,
and shock (7), with cardiac magnetic resonance im-
aging evidence of diffuse myocardial edema and
gadolinium enhancement (8). However, in another
isolated autopsy report from a patient who suffered
from SARS-CoV-2–related pneumonia and cardiac ar-
rest, no obvious histological changes in the myocar-
dium were observed with the exception of few
interstitial mononuclear inflammatory infiltrates (9).
Elevated troponin levels have also been observed
in those with worse clinical outcomes. In a retro-
spective, single-center analysis of 416 hospitalized
patients with confirmed COVID-19, 19.7% displayed
evidence of cardiac injury, as defined by elevated
high-sensitivity troponin I levels greater than the
99th percentile upper limit. Those with confirmed
cardiac injury tended to be older (median age of 74 vs.
60 years) and suffer from hypertension (59.8% vs.
23.4%), diabetes (24.4% vs. 12.0%), coronary heart
disease (29.3% vs. 6.0%), heart failure (14.6% vs.
1.5%), or cancer (8.5% vs. 0.6%) (10).
COVID-19 IN PATIENTS WITH CARDIOVASCULAR
RISK FACTORS OR DISEASE. Patients with cardio-
vascular risk factors or disease are at increased risk of
suffering from worse clinical outcomes with COVID-
19. In an analysis of 2 cohorts from Jinyintan Hospi-
tal and Wuhan Hospital of 191 patients, patients with
hypertension, diabetes, or coronary heart disease
were at increased risk of in-hospital mortality (11).
The prevalence of hypertension among nonsurvivors
was 48% as compared to 30% in survivors; 31% versus
19% for diabetes, and 13% versus 8% for cardiovas-
cular disease. These comorbidities were also more
likely to be present in patients who required intensive
care unit admission (4). Other studies, including a
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recently published meta-analysis of 46,248 infected
patients, have corroborated the observation that pa-
tients with cardiovascular risk factors or cardiovas-
cular disease have worse clinical outcomes (12) and
also suggest that hypertension (17  7%; 95% confi-
dence interval [CI]: 14% to 22%), diabetes (8  6%;
95% CI: 6% to 11%), and cardiovascular disease (5 
4%; 95% CI: 4% to 7%) were prevalent comorbidities
among infected patients. Recent studies have also
demonstrated that age and hypertension were pre-
dictors of an increased likelihood of cardiovascular
complications, and cardiovascular complications
were associated with a 4.26-fold increased risk of
death (95% CI: 1.9 to 9.49) (10).
COVID-19 IN PATIENTS WITH HEART TRANS-
PLANTATION. There have been case series published
on COVID-19 infection in heart transplant recipients.
Two confirmed cases suggest similar presentations to
nontransplant recipients and both patients demon-
strated clinical improvement. A questionnaire of 87
heart transplant recipients in China, of which
importantly 96.6% undertook quarantine procedures,
did not suggest a markedly elevated rate of SARS-
CoV-2 infection in this population (13,14).
COVID-19 IN PATIENTS WITH CANCER. In a retro-
spective medical review of 1,524 patients with cancer
who were admitted to the Department of Radiation
and Medical Oncology in Zhongnan Hospital of
Wuhan University from December 30, 2019, to
February 17, 2020, the infection rate of SARS-CoV-2 in
patients with cancer was 0.79% (95% CI: 0.3% to 1.2%)
(15). In contrast, the estimated cumulative incidence
of all COVID-19 cases in Wuhan was 0.37%. As a
result, the odds of infection in patients with cancer
were estimated to be 2.31 (95% CI: 1.89 to 3.02)
greater. Patients with cancer who were infected had a
median age of 66 years and were more likely to have
non–small cell lung cancer (58.3%). Five of these pa-
tients were being treated with chemotherapy,
immunotherapy, or radiation therapy. Three deaths
were recorded.
In a multicenter, prospective cohort study of 2,007
cases from 575 hospitals, 1% of the 1,590 COVID-19
cases had a history of cancer (15). This in contrast to
an incidence of cancer in the Chinese population of
0.29% per 100,000 people. Again, among those
infected, lung cancer was most common, and patients
tended to be older. Patients with cancer also suffered
from an increased risk of adverse events that tended
to occur earlier, including admission to the intensive
care unit, need for invasive ventilation, or death,
which occurred in 7 of 18 patients (39%), compared
with 124 of 1,572 patients without cancer (8%).
Patients with cancer who were recently treated with
chemotherapy or surgery were also more likely to
suffer from clinically severe adverse events. Howev-
er, there is a critical need for additional studies to
validate these early observations.
THE CoV FAMILY
CoVs represent a large family of hundreds of envel-
oped, single-stranded, positive-sense ribonucleic
acid (RNA) viruses that establish an infection pri-
marily by targeting the mucosal surfaces of respira-
tory and intestinal tracts of a wide range of mammals
and birds. There are 4 main subgroupings of CoVs:
alpha, beta, gamma, and delta (16). The 7 CoVs that
are capable of infecting humans include 229E (alpha
CoV), NL63 (alpha CoV), OC43 (beta CoV), HKU1 (beta
CoV), Middle East respiratory syndrome (MERS)-CoV
(beta CoV), SARS-CoV (beta CoV), and SARS-CoV-2
(beta CoV). The prototype human CoV isolates 229E
and OC43 have been causally linked to the common
cold. SARS-CoV is the cause of the SARS, whereas
MERS-CoV was established as the cause of MERS.
Identification and sequencing of the virus responsible
for COVID-19 established that it was a novel CoV that
shared 88% sequence identity with 2 bat-derived
SARS-like CoVs (16). Subsequently, the 2019 novel
CoV was shown to share a 79.5% sequence homology
with SARS-CoV and was subsequently renamed SARS-
CoV-2 (16). The genome of the CoVs encodes 4 major
structural proteins: the spike (S) protein, nucleo-
capsid protein, membrane protein, and the envelope
protein (Central Illustration). The S protein is respon-
sible for facilitating entry of the CoV into the target
cell (16,17) and is composed of a short intracellular
tail, a transmembrane anchor, and a large ectodomain
that consists of a receptor binding S1 subunit and a
membrane-fusing S2 subunit (16).
CoV VIROLOGY
Given that far more is known with respect to the
virology of SARS-CoV than of SARS-CoV-2, and given
that these 2 CoVs appear to have some overlapping
biology and clinical presentations, we will discuss
these 2 viruses together, with an emphasis on the
most recent studies that have revealed unique bio-
logical aspects of SARS-CoV-2. We will review viral
attachment, entry, and replication of SARS-CoV and
SARS-CoV-2 in host cells. This discussion will be in-
tegrated with a review of the ongoing clinical trials
that target these different aspects of the biology of
SARS-CoV-2 (see Tables 1 to 5).
Angiotensin-converting enzyme 2 (ACE2) is the
entry receptor for SARS-CoV and SARS-CoV-2. Viruses
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enter cells by binding to host cell-encoded proteins
that facilitate the entry of the virus into the cell, as
well as allow the virus to survive and replicate within
the cell. Some viruses, including certain strains of
CoVs are capable of down-modulating the entry re-
ceptor once they gain access to the cell. Receptor
down-modulation is a strategy broadly used by many
viruses to escape the immune system, as well as
establish the best environment for viral replication
and spread (18). Receptor down-modulation may also
disrupt many of the natural physiologic functions of
the host cell, resulting in cell death leading to organ
level dysfunction.
The entry receptor utilized by both SARS-CoV and
SARS-CoV-2 is ACE2 (Central Illustration), which is a
type I transmembrane carboxypeptidase with 40%
homology to ACE. ACE plays a critical role in
activation of the RAS, by processing angiotensin I
(angiotensin 1-10) to angiotensin II (angiotensin 1-8),
the major effector peptide of RAS, which mediates its
effects through selective interactions with G-protein–
coupled angiotensin II type 1 (AT1) and type 2 (AT2)
receptors (19). ACE, however, has not been implicated
in the entry of human CoVs into cells.
ACE2 is highly expressed in the mouth, tongue,
and types I and II alveolar epithelial cells in the lungs.
ACE2 is also abundantly expressed by cardiovascular
endothelium, cardiac myocytes, cardiac fibroblasts,
as well as epithelial cells of the kidney and testis. The
major substrate of ACE2 is angiotensin II, which is
cleaved to angiotensin 1-7 (Figure 1) and functions
through association with the G-protein–coupled re-
ceptor Mas receptor. The ACE2–angiotensin (1–7)–Mas
receptor axis is regarded as the counter-regulatory
CENTRAL ILLUSTRATION SARS-CoV-2 Structure and Entry Into Cells
Ky, B. et al. J Am Coll Cardiol Basic Trans Science. 2020;5(5):501–17.
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) virus genome encodes 4 major structural proteins: the spike (S) protein;
the nucleocapsid (N) protein; the membrane (M) protein; and the envelope (E) protein. The S protein is responsible for facilitating entry of the
CoV into the target cell. The routes employed by SARS-CoV include endocytosis and membrane fusion. The route employed by SARS-CoV-2
is via endocytosis; whether SARS-CoV-2 enters cells by membrane fusion is not known. Binding of the S protein of SARS-CoV to angiotensin-
converting enzyme 2 (ACE2) leads to the uptake of the virions into endosomes, where the viral S protein is activated by the pH-dependent
cysteine protease cathepsin L. Activation of the S protein by cathepsin L can be blocked by bafilomycin A1 and ammonium chloride, which
indirectly inhibit the activity of cathepsin L by interfering with endosomal acidification. Chloroquine and hydroxychloroquine are weak bases
that diffuse into acidic cytoplasmic vesicles such as endosomes, lysosomes, or Golgi vesicles and thereby increases their pH. MDL28170
inhibits calpain and cathepsin L. SARS-CoV can also directly fuse with host cell membranes, after processing of the virus spike protein by
transmembrane protease serine 2 (TMPRSS2), a type II cell membrane serine protease. Camostat mesylate is an orally active serine protease
inhibitor. Modified from Simmons et al. (25). RNA ¼ ribonucleic acid.
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arm of the RAS by opposing the effects of the ACE–
angiotensin II axis–AT1. Although the precise role of
ACE2 is still being evaluated, studies been shown that
ACE2 exerts protective effects in the pulmonary and
the cardiovascular systems, where it serves to oppose
the deleterious effects of RAS activation (20–22).
Infection with SARS-CoV and SARS-CoV-2 is trig-
gered by binding of the S protein on the surface of the
CoV to ACE2 that is expressed on the cell surface. The
receptor binding domain of the S protein of SARS-
CoV-2 is located on the S1 subunit, which undergoes
a conformational change when it binds to ACE2,
which facilitates viral attachment to the surface of
target cells (17). Binding of SARS-CoV-2 to ACE2 can
result in uptake of virions into endosomes (Central
Illustration). Viral entry into the cell requires prim-
ing of the S protein by the serine protease trans-
membrane protease serine 2 (TMPRSS2), which
cleaves the viral S protein at the S1/S2 and the S20 site
and allows fusion of viral and cellular membranes
(23). The S proteins of SARS-CoV-2 can also use pH-
sensitive endosomal proteases (cathepsin B and L)
for priming and entry into cells. Interestingly, the
binding affinity of the SARS-CoV-2 S ectodomain to
ACE2 is 10- to 20-fold higher than the binding of the
SARS-CoV ectodomain to ACE2 (17). The increase in
stickiness of the SARS-CoV-2 capsid S protein makes
disease transmission more likely and might explain
the increased person-to-person transmission with
SARS-CoV-2 compared with that of SARS-CoV. Insofar
as the viral S proteins are the part of the virus that
interacts with the immune system, they may serve as
a promising target for vaccines. Relevant to this dis-
cussion, convalescent sera from patients with SARS
have been shown to block the entry of SARS-CoV-2
entry into cultured cells, albeit with less efficiency
that SARS-CoV (23). However, monoclonal antibodies
raised against the receptor binding domain of the S1
protein of SARS-CoV do not bind to the receptor
binding domain of the S1 protein of SARS-CoV-2,
suggesting that SARS-directed antibodies are not
cross reactive and that SARS-CoV-2 proteins are
necessary to develop effective antibodies. Although
ACE inhibitors do not inhibit ACE2, Hoffman et al. (23)
demonstrated that anti-ACE2 antibody prevented
entry of viral vectors into cell lines expressing the
SARS-CoV-2 S protein.
INTERACTION OF CoV WITH THE RAS. An additional
layer of complexity to understanding the patho-
physiology of the SARS-CoV-2 in humans stems from
the complexity of the interactions of CoVs with the
RAS (Figure 1), as well as the widespread use of drugs
that interfere with the RAS, including ACE
inhibitors, angiotensin-receptor antagonists, or
angiotensin receptor-neprilysin inhibitors. Each of
these drugs has different effects on the expression of
the various components of the RAS in different tissue
beds. Here we will briefly discuss these important
interactions, as well as their implications for the
treatment of patients with COVID-19.
Previous studies have shown that SARS-CoV S pro-
teins induce the expression of a cell surface metal-
loenzyme termed a disintegrin andmetalloproteinase-
17, which was originally described as the enzyme that
cleaves membrane-bound tumor necrosis factor-a
from the cell surface and allows it circulate in the sol-
uble form of tumor necrosis factor-a (24). As shown
in Figure 1, activation of a disintegrin and
metalloproteinase-17 results in the proteolytic cleav-
age of ACE2 (referred to as shedding) from the cell
surface, with the release of the catalytically active
TABLE 1 Select Treatment Trials Targeting RAS
Drug Name
Mechanism of
Action NCT Number Title Study Population
Targeted
Enrollment Study Design
Primary Outcome
Measure
Losartan Anti-RAS NCT04312009 Losartan for Patients
With COVID-19
Requiring
Hospitalization
Age $18 yrs with presumptive positive laboratory
test for SARS-CoV-2; admission to the hospital
with a sequential organ failure assessment score
$1 and increased oxygen requirement;
randomization within 24 h of presentation
200 Randomized, double-
blind, placebo
controlled
Difference in
oxygenation
status at 7 days
Losartan Anti-RAS NCT04311177 Losartan for Patients
With COVID-19
Not Requiring
Hospitalization
Age $18 yrs with presumptive positive laboratory
test for SARS-CoV-2 or URI or fever
516 Randomized, double-
blind, placebo
controlled
Hospital admission
up to 15 days
For an up-to-date listing of trials, search for “COVID-19” at the ClinicalTrials.gov website.
COVID-19 ¼ coronavirus disease-2019; NCT ¼ national clinical trial; OFA ¼ organ failure assessment; RAS ¼ renin-angiotensin system; SARS-CoV-2 ¼ severe acute respiratory syndrome coronavirus-2;
URI ¼ upper respiratory infection.
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TABLE 2 Select Treatment and Prophylaxis Trials Targeting Viral Cell Entry
Drug Name
Mechanism of
Action NCT Number Title Study Population
Targeted
Enrollment Study Design
Primary Outcome
Measure
Treatment Trials
Camostat Viral entry NCT04321096 The Impact of Camostat
Mesylate on COVID-19
Infection (CamoCo-19)
Age 18–110 yrs, COVID-19–
confirmed hospitalized
patients (<48 h) or if
hospital-acquired COVID-19
is suspected, <48 h since
onset of symptoms
180 Randomized, double-
blind placebo
controlled, phase
IIa trial
Time to clinical
improvement
at 30 days
Hydroxychloroquine Viral entry NCT04315896 Hydroxychloroquine
Treatment for Severe
COVID-19 Pulmonary
Infection (HYDRA Trial)
Age 18–80 yrs, COVID-19
confirmed by RT-PCR in
any respiratory sample;
severe disease defined by
pulse O2< 91%, 3%
decline from baseline
pulse O2, or need for
increased supplemental
O2, mechanical ventilation,
or sepsis
500 Randomized, double-
blind, placebo
controlled
All-cause hospital
mortality at
120 days
Hydroxychloroquine Viral entry NCT04316377 Norwegian Coronavirus
Disease 2019 Study
(NO COVID-19)
Age >18 yrs, hospitalized,
moderately severe disease
(NEWS score #6);
SARS-CoV-2–positive test
202 Randomized,
open, single arm
Rate of decline in
SARS-CoV viral load
at 96 h
Prophylaxis Trials
Chloroquine phosphate Viral entry NCT04303507 Chloroquine/
Hydroxychloroquine
Prevention of
Coronavirus Disease
(COVID-19) in the
Healthcare Setting
(COPCOV)
Age $16 yrs; health care
worker or front-line
participant with patient
contact working in a
health care facility;
inpatient or relative of a
patient and likely exposed
to COVID-19; agree to not
self-medicate with
potential antivirals
40,000 Randomized, double-
blind, placebo
controlled
Number of
symptomatic
COVID-19
infections
Severity of
symptoms
Hydroxychloroquine Viral entry NCT04308668 Post-exposure
Prophylaxis/Pre-
emptive Therapy for
SARS-Coronavirus-2
(COVID-19 PEP)
Age >18 yrs; exposure to a
COVID-19 case within
4 days as either a health
care worker or household
contact; symptomatic
COVID-19 case with
confirmed diagnosis within
4 days of symptom onset;
or symptomatic health
care worker with known
COVID-19 contact and
within 4 days of symptom
onset
3,000 Randomized, double-
blind, placebo
controlled
Incidence of
COVID-19
disease at
14 days
Ordinal Scale of
COVID-19
disease severity
at 14 days
Hydroxychloroquine Viral entry NCT04318444 Hydroxychloroquine Post
Exposure Prophylaxis
for Coronavirus Disease
(COVID-19)
Age >18 yrs; household
contact of index case:
currently residing in the
same household as an
individual evaluated at
NYP via outpatient, ED, or
inpatient services who:
1) tests positive for
COVID-19, or 2) is defined
as suspected case, or PUI,
by the treating physician
1,600 Randomized, double-
blind, placebo
controlled
Symptomatic, lab-
confirmed
COVID-19
Hydroxychloroquine Viral entry NCT04318015 Hydroxychloroquine
Chemoprophylaxis in
Healthcare Personnel in
Contact With COVID-19
Patients (PHYDRA
Trial)
Age >18 yrs; health care
personnel exposed to
patients with COVID-19
respiratory disease
(physicians, nurses,
chemists, pharmacists,
janitors, stretcher-bearer,
administrative, and
respiratory therapists)
400 Randomized, double-
blind, placebo
controlled
Symptomatic
COVID-19
infection rate
at 60 days
For an up-to-date listing of trials, search for “COVID-19” at the ClinicalTrials.gov website.
ED ¼ emergency department; NEWS ¼ National Early Warning Score; NYP ¼ New York Presbyterian; PUI ¼ person under investigation; RT-PCR ¼ reverse transcriptase-polymerase chain reaction; other
abbreviations as in Table 1.
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soluble angiotensin-converting enzyme 2 (sACE2)
ectodomains into the circulation (22,25). A decrease in
ACE2 levels on the cell surface would be expected to
result in a decrease in the levels of angiotensin 1-7
(cytoprotective) and a corresponding increase in tissue
levels of angiotensin II (proinflammatory and profi-
brotic). The importance of SARS-CoV2–induced down-
regulation of cell surface ACE2 was demonstrated in
experimental studies, wherein administration of re-
combinant human ACE2 protein, genetic deletion of
the AT1 receptor, or administration of an AT1 receptor
antagonist were shown to be protective in acute lung
injury models (21,22). These and other observations
have suggested that the use of AT1 receptor antago-
nists may be beneficial in patients with COVID-19 (26),
and consistent with this, losartan is currently being
tested in randomized, double-blind placebo controlled
studies as a potential therapy in hospitalized infected
patients (Table 1). Relevant to this discussion, the ACE
inhibitors in clinical use do not directly affect ACE2
activity (27). The biological significance of circulating
sACE2 is not known. Of note, sACE2 retains its ability to
bind the S protein of SARS-CoV and was shown to
prevent entry of SARS-CoV into cells in vitro (28).
Thus, sACE2 may act as a decoy receptor that prevents
SARS-CoV-2 from binding to ACE2 on the cell surface.
APN01 is a human recombinant sACE2 that has been
shown to block the early stages of SARS-CoV-2 in-
fections in cell culture and human tissue organoid
cultures (29). APN01 has already undergone safety and
tolerability testing in a phase II trial of healthy volun-
teers (NCT00886353), but at the time of this writing is
not being tested clinically in patients with COVID-19.
The recognition that many patients with COVID-19
have underlying medical conditions that are treated
with ACE inhibitors and AT1 receptor antagonists
(30), coupled with the knowledge that higher urinary
ACE2 levels have been observed in patients treated
with AT1 receptor antagonists (26), has given rise to
the concern that pharmacologic up-regulation of
ACE2 by RAS inhibitors may influence the infectivity
of SARS-CoV-2 in a patient population that is already
at high risk for severe COVID-19 infection (31). How-
ever, as noted in a recent review (32) on this topic, the
experimental and clinical data often yield conflicting
results with respect to the role of ACE inhibitors and
AT1 receptor antagonists on ACE2 levels in different
pathophysiological contexts. These conflicting results
suggest that the effects on RAS inhibitors on ACE2 are
complex and nuanced and should not be assumed to
be the same for all RAS inhibitors, nor should it be
assumed that changes in ACE2 levels in the heart or
other tissues necessarily reflect changes in ACE2
levels in the lung, which is the portal of entry for
SARS-CoV-2. Given that we have limited under-
standing with respect to the interaction of RAS in-
hibitors, ACE2 levels, and SARS-CoV-2 infectivity in
humans, we do not believe that it is possible to make
definitive statements that go beyond the joint state-
ment issued on March 17, 2020, by the Heart Failure
Society of America, American College of Cardiology,
and American Heart Association, that recommended
“continuing renin-angiotensin-aldosterone system
antagonists for those patients who are currently pre-
scribed such agents for indications for which these
agents are known to be beneficial” (33).
ENTRY OF SARS-CoV AND SARS-CoV-2 INTO
CELLS. The entry of enveloped viruses into host cells
occurs through 2 primary mechanisms: the first is
direct fusion of the viral membrane with the plasma
membrane of the host cells, which allows the virus to
directly deliver its genomic material into the cytosol;
and the second is that the virus hijacks the cell’s
endocytic machinery, by binding to a cell surface
receptor, which then triggers endocytosis of the
virus-receptor complex (Central Illustration). In the
endocytic pathway, the endocytosed virions are
subjected to an activation step within the endosome,
which is typically mediated by the acidic environ-
ment of the endosome, resulting in fusion of the viral
and endosomal membranes, which allows for the
release of the viral genome into the cytosol. Several
viruses, including human immunodeficiency virus
and SARS-CoV use direct membrane fusions at the
cell surface or endocytosis to enter cells. As noted,
recent studies suggest that SARS-CoV-2 binds to
ACE2, which leads to endocytosis of the receptor-
virus complex (23). What is not known at this time
is whether SARS-CoV-2 is also capable of directly
fusing with the lipid membrane of cells. However,
based on the similarities of how SARS-CoV and SARS-
CoV-2 behave, it is likely that their modes of entry
into cells will be similar. Understanding these dif-
ferences in cell entry has implications for developing
novel therapeutics.
THERAPEUTICS TARGETING ENDOCYTOSIS. The
entry of SARS-CoV into cells was shown to occur by
direct fusion of the viral membranes with the plasma
membrane of the host cell (Central Illustration),
through a process that requires processing of the viral
S protein by TMPRSS2 at or near the cell surface.
Processing of the S protein exposes the fusion peptide
of the S protein that inserts into the cell membrane,
which brings the envelope of the viral membrane into
closer approximation with the membrane of the host
cell, thereby facilitating fusion (34). At the time of
this writing, the uptake of SARS-CoV-2 into cells has
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been shown to occur through endocytosis of the
SARS-CoV-2–ACE2 complex, which also requires
priming of the S protein by TMPRSS2. It is not known
whether SARS-CoV-2 also enters though direct fusion.
Based on the evidence linking TMPRSS2-mediated
SARS-CoV-2 activation to SARS-CoV-2 infectivity
(23,35), the small molecule serine protease inhibitor
camostat mesylate may also be an attractive target for
clinical trials with SARS-CoV-2 (Table 2). Camostat
mesylate has already been shown to inhibit replica-
tion of influenza and parainfluenza viruses and to
prevent the development of pneumonia and viral
myocarditis in infected mice (36). Given that the
SARS-CoV-2 S protein is activated by the pH-
dependent cysteine protease cathepsin L, this pro-
cessing step may be sensitive to inhibition with drugs
that indirectly inhibit cathepsin L activity by inter-
fering with endosomal acidification (e.g., bafilomycin
A1) or by compounds that directly block the proteo-
lytic activity of cathepsin L.
It has also been suggested that the antimalarial
drugs chloroquine and hydroxychloroquine might
exert a potent antiviral effect by virtue of their ability
to increase endosomal pH. Inside cells, chloroquine
and hydroxychloroquine are rapidly protonated and
concentrated in endosomes. The positive charge of
the chloroquine increases the pH of the endosome,
which prevents cathepsin-induced priming of the
viral S protein. Both chloroquine and hydroxy-
chloroquine decrease SARS-CoV-2 replication in
cultured cells; however, hydroxychloroquine is more
potent than chloroquine (37). In a small single-arm
study of patients with confirmed COVID-19, treat-
ment with hydroxychloroquine was associated with a
significant difference in clearing of viral nasopha-
ryngeal carriage of SARS-CoV-2 within 3 to 6 days
when compared with that of untreated control sub-
jects that were studied at 3 to 6 days. Azithromycin
when added to hydroxychloroquine was significantly
more efficient for virus elimination (38). However,
both therapies can result in QT prolongation, and as
such, caution needs to be exercised when using these
therapies together. Chloroquine and hydroxy-
chloroquine can also manifest in cardiotoxicity,
including cardiomyopathy, both systolic and dia-
stolic, atrioventricular block, and bundle branch
TABLE 3 Select Treatment Trials Targeting Viral Replication
Drug Name
Mechanism of
Action NCT Number Title
Umifenovir Antiretroviral NCT04260594 Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of
Pneumonia Caused by Novel Coronavirus
ASC09 þ ritonavir; lopinavir þ ritonavir Antiretroviral NCT04261907 Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and
Lopinavir/Ritonavir for Novel Coronavirus Infection
Darunavir þ cobicistat Antiretroviral NCT04252274 Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19
(DC-COVID-19)
Lopinavir þ ritonavir; umifenovir Antiretroviral NCT04252885 Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus
Infection (ELACOI)
Lopinavir þ ritonavir Antiretroviral NCT04330690 Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial (CATCO)
Remdesivir Antiretroviral NCT04280705 Adaptive COVID-19 Treatment Trial (ACTT)
Remdesivir Antiretroviral NCT04292899 Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734)
in Participants With Severe Coronavirus Disease (COVID-19)
Remdesivir Antiretroviral NCT04292730 Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734)
in Participants With Moderate Coronavirus Disease (COVID-19)
Compared to Standard of Care Treatment
For an up-to-date listing of trials, search for “COVID-19” at the ClinicalTrials.gov website.
ECMO ¼ extracorporeal membrane oxygenation; FiO2 ¼ fraction of inspired O2; nCoV ¼ novel coronavirus; PaO2 ¼ partial arterial O2 pressure; PCR ¼ polymerase chain reaction; RR ¼ respiratory rate; other
abbreviations as in Tables 1 and 2.
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block (39). Hydroxychloroquine will be used as one of
the treatment arms in the World Health Organization
(WHO) multinational SOLIDARITY (Efficacy of
Different Antiviral Drugs in SARS-CoV-2) trial (40)
and is also currently being investigated in a number
of other studies (Tables 2 and 5). Interestingly, amio-
darone, which is a cationic amphiphile, was shown to
inhibit Ebola virus infection in vitro in target cells,
using concentrations of amiodarone that overlapped
those detected in the sera of patients treated for ar-
rhythmias. Both amiodarone and its main metabolite,
monodesethyl amiodarone, were shown to interfere
with the fusion of the viral envelope with the endo-
somal membrane, thus blocking viral replication (41).
Amiodarone has also been shown to inhibit SARS-CoV
infection and spreading in vitro by altering the late
compartments of the endocytic pathway by acting
after the transit of the virus through endosomes (42).
REPLICATION OF SARS-CoV IN HOST CELLS.
Because of the exceptionally large size of the CoV
RNA genome (w30 kb) and the complexity of CoV-
host cell interactions, coupled with the novelty of
the SARS-CoV-2 genome, very little is known
regarding SARS-CoV-2 replication in cells, let alone
how the virus interacts with the host. Given that
antiviral strategies are being considered for treatment
of patients with COVID-19, here we will review what
is generally understood about SARS-CoV replication
in mammalian cells, recognizing that this information
may change as we learn more about SARS-CoV-2
(see Figure 2).
Once the genomic RNA of SARS-CoV is released
into the cytoplasm of the host cell, the positive-
strand viral RNA is translated on host ribosomes
into a large polypeptide termed the replicase, which
undergoes proteolytic cleavage to yield proteins that
are required from genome replication, including a
viral RNA-dependent RNA polymerase. The viral
RNA-dependent RNA polymerase generates a full-
length, antisense negative-strand viral RNA tem-
plate, which is used for replicating positive strand
viral genomic RNA, as well as shorter subgenomic
negative strand RNAs that serve as templates for
synthesizing messenger RNAs that code for structural
proteins of the virus, including the S, membrane,
TABLE 3 Continued
Study Population
Targeted
Enrollment Study Design Primary Outcome Measure
Age $18 yrs; subjects with pneumonia diagnosed as 2019-nCoV infection;
detection of 2019-nCoV nucleic acid–positive by RT-PCR in respiratory
tract or blood samples; virus gene sequence of respiratory tract or
blood samples is highly homologous to the known 2019-nCoV
380 Randomized, single-arm, open-label
umifenovir
Negative viral conversion rate at 7 days
Age between 18 to 75 yrs; lab (RT-PCR) and clinically confirmed case of
2019-nCoV pneumonia; hospitalized with a new onset respiratory
illness (#7 days since illness onset)
160 Randomized, open-label ASC09/
ritonavir or lopinavir/ritonavir
The incidence of adverse outcomes, defined
by at least 1 of the following: pulse
O2 #93% without O2 supplementation,
PaO2-to-FiO2 ratio #300 or RR $30
breaths/min assessed at 14 days
Pneumonia caused by 2019-nCoV 30 Randomized, open-label,
single-arm
The viral clearance rate of throat swabs,
sputum, or lower respiratory tract
secretions at day 7
Age 18–80 yrs; confirmation of SARS-CoV-2 infection by RT-PCR with
normal kidney and liver function
125 Randomized, open-label (1:1:1) to
lopinavir þ ritonavir; or
umifenovir; or standard care
The rate of viral inhibition, as determined by
RT-PCR at days 2, 4, 7, 10, 14, and 21
Age >6 months with confirmed SARS-CoV-2 by RT-PCR, admitted to
hospital
440 Randomized, open-label (1:1) of
lopinavir þ ritonavir or
standard care
Efficacy of intervention at 29 days as
determined by 10-point ordinal scale of
clinical status
Age 18–99 yrs, PCR-confirmed novel coronavirus infection by lab assay;
illness as defined by abnormal radiographic imaging, clinical
assessment, and pulse O2 #94%, requiring O2, or requiring mechanical
ventilation
572 Adaptive, randomized, double-blind
placebo controlled
Time to recovery at day 29
Age $18 yrs; confirmation of SARS-CoV-2 infection by RT-PCR #4 days
before randomization; current hospitalization with pulse O2 #94%
6,000 Randomized, open-label study of
remdesivir 5 days; or remdesivir
10 days
Odds of clinical improvement on a 7-point
ordinal scale by day 11
Age $18 yrs; confirmation of SARS-CoV-2 infection by RT-PCR #4 days
before randomization; current hospitalization with fever, pulse
O2 >94%, radiographic evidence of pulmonary infiltrates
1,600 Randomized, open-label study of
remdesivir 5 days; or remdesivir
10 days; or standard of care
Odds of clinical improvement on a 7-point
ordinal scale by day 11
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envelope, and nucleocapsid proteins. Translation of
viral messenger RNAs occurs using the host endo-
plasmic reticulum. Once the viral structural proteins,
S, envelope, and membrane, are translated in the
endoplasmic reticulum, they move along the secre-
tory pathway to the endoplasmic reticulum-Golgi in-
termediate compartment. There, the viral proteins
become encapsulated and bud into membranes con-
taining viral structural proteins. Following assembly
and maturation, virions are transported to the cell
surface in vesicles and released by exocytosis (43,44).
THERAPEUTICS FOR VIRAL REPLICATION. There are
a number of antiviral drugs that are being repurposed
for the treatment of SARS-CoV-2. A partial list of these
antiviral drugs are discussed next.
Nuc leos ide ana logs . Remdesivir (GS-5734, Gilead
Sciences, Inc., Foster City, California) is a nucleoside
TABLE 4 Select Treatment and Prophylaxis Trials Targeting the Immune System
Drug Name Mechanism of Action NCT Number Title Study Population
Targeted
Enrollment Study Design
Primary Outcome
Measure
Treatment Trials
IFN-a1b Immunomodulatory NCT04293887 Efficacy and Safety
of IFN-a1b in the
Treatment of Novel
Coronavirus
Patients
Age $18 yrs with clinically
diagnosed coronavirus
pneumonia within
7 days, including
RT-PCR evidence of
coronavirus and
symptoms
328 Randomized, open-
label, single-arm
Incidence of side
effects within
14 days
including
dyspnea, pulse
O2 #94%, and
RR $24
breaths/min
Methylprednisolone Immunomodulatory NCT04273321 Efficacy and Safety
of Corticosteroids
in COVID-19
Age >18 yrs, diagnosis of
novel coronavirus
pneumonia (COVID-19)
400 Randomized, open-
label, single-arm
Incidence of
treatment
failure in
14 days
Methylprednisolone Immunomodulatory NCT04244591 Glucocorticoid Therapy
for COVID-19
Critically Ill Patients
With Severe Acute
Respiratory Failure
Age >18 yrs, RT-PCR–
confirmed infection,
symptoms for >7 days,
PaO2/FiO2 <200,
positive pressure
ventilation or HFNC
higher than 45 l/min
for <48 h, requiring ICU
admission
80 Randomized, open-label
of glucocorticoid
therapy or standard
of care
Murray lung injury
score at 7 days
Sarilumab Immunomodulatory NCT04315298 Evaluation of the
Efficacy and Safety
of Sarilumab in
Hospitalized
Patients With
COVID-19
Age $18 yrs; confirmation
of SARS-CoV-2 infection
by RT-PCR; current
hospitalization with
evidence of pneumonia
and severe disease,
critical disease, or
multiorgan system
dysfunction
400 Adaptive, randomized,
double-blind,
placebo-controlled
with high and low
doses
Percent change in
C-reactive
protein levels
at 4 days
Percentage of
patients
reporting
clinical severity
rated on a
7-point ordinal
scale
Siltuximab Immunomodulatory NCT04329650 Efficacy and Safety
of Siltuximab vs.
Corticosteroids in
Hospitalized
Patients With
COVID-19
Pneumonia
Age $18 yrs;
confirmation of
SARS-CoV-2
infection by
RT-PCR; current
hospitalization with
evidence of pneumonia;
maximum O2 support of
35%
100 Randomized, open-label
of siltuximab or
methylprednisolone
Proportion of
patients
requiring ICU
admission at
29 days
Tocilizumab Immunomodulatory NCT04317092 Tocilizumab inCOVID-19
Pneumonia
(TOCIVID-19)
No age or sex limit;
SARS-CoV-2
infection by
RT-PCR, current
hospitalization
secondary to
pneumonia; pulse
O2 #93%, requiring O2,
or requiring mechanical
ventilation (invasive or
noninvasive)
400 Open-label, single-arm Mortality at
1 month
Continued on the next page
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analog that exhibits broad antiviral activity. Remde-
sivir is a prodrug that is metabolized to its active form
GS-441524, which interferes with the action of viral
RNA-dependent RNA polymerase, resulting in a
decrease in viral RNA production. It is not known,
however, whether remdesivir terminates RNA chains
or causes mutations in them. Remdesivir was effec-
tive against multiple types of CoVs in cell culture and
a mouse model of SARS (45); however, it did not show
an effect in patients with Ebola. Remdesivir is
currently being tested in several clinical trials for
hospitalized patients with COVID-19 and pneumonia
(Tables 3 and 5). Remdesivir is also 1 of the 4 treat-
ment arms in the multinational SOLIDARITY trial,
which is the World Health Organization’s sponsored
multinational randomized, open clinical trial to
evaluate the safety and comparative efficacy of
hydroxychloroquine, remdesivir, the combination of
lopinavir and ritonavir, and the combination lopina-
vir and ritonavir plus interferon-beta (40). SOLI-
DARITY will use an adaptive design, which will allow
for discontinuation of drugs that lack effectiveness,
as well as adding new drugs that appear promising.
This type of trial design offers flexibility and effi-
ciency, particularly in the identification of early sig-
nals related to either efficacy or toxicity, while
maintaining study validity (46).
Favipiravir (Avigan, Fujifilm Toyama Chemical,
Tokyo, Japan) is another nucleoside analog antiviral
drug that inhibits viral RNA-dependent RNA poly-
merase. Like remdesivir, it is a prodrug that is
metabolized to its active form, favipiravir-ribofur-
anosyl-5’-triphosphate. Although favipiravir has un-
dergone phase III clinical trials for the treatment of
influenza, it is not yet approved by the U.S. Food and
Drug Administration (FDA). Japan has granted
approval for favipiravir for treating viral strains un-
responsive to current antivirals. In preliminary
studies, favipiravir was shown to have more potent
antiviral activity than lopinavir/ritonavir (47).
Ribavirin (Copegus, Genentech Inc., San Francisco,
California) is a prodrug that acts as nucleoside in-
hibitor. The metabolites of ribavirin resemble aden-
osine or guanosine nucleosides that then become
incorporated into viral RNA and inhibit RNA-
dependent replication in RNA viruses. Ribavirin is
currently FDA-approved for the treatment of chronic
hepatitis C virus infection in combination with
peginterferon alfa-2a (Pegasys, Genentech).
Protease inh ib i tors . Lopinavir is a protease inhibi-
tor class that is used in fixed-dose combination with
another protease inhibitor, ritonavir (lopinavir/rito-
navir [Kaletra, AbbVie Inc., North Chicago, Illinois])
for the treatment of human immunodeficiency virus.
TABLE 4 Continued
Drug Name Mechanism of Action NCT Number Title Study Population
Targeted
Enrollment Study Design
Primary Outcome
Measure
Tocilizumab Immunomodulatory NCT04320615 A Study to Evaluate
the Safety and
Efficacy of
Tocilizumab in
Patients With
Severe COVID-19
Pneumonia
(COVACTA)
Age $18 yrs; hospitalized
with COVID-19
pneumonia per WHO
criteria; pulse O2 #93%
or PaO2/FiO2 <300
330 Randomized, double-
blind placebo
controlled
Clinical status
using a
7-category
ordinal scale at
28 days
Anakinra,
siltuximab,
or tocilizumab
Immunomodulatory NCT04330638 Treatment of COVID-19
Patients With Anti-
interleukin Drugs
(COV-AID)
Age $18 yrs; hospitalized with
confirmed COVID-19
diagnosis by RT-PCR or
other laboratory test;
hypoxia defined by PaO2/
FiO2; CXR or CT scan with
bilateral infiltrates
342 Randomized, open-label
(1:1:1:1) to anakinra,
or siltuximab, or
anakinra þ siltuximab,
or tocilizumab, or
anakinra þ tocilizumab
Time to clinical
improvement at
15 days
Prophylaxis Trial
Recombinant human
IFN-a1b and
thymosin a1
Immunomodulatory NCT04320238 Experimental Trial of
rhIFNa Nasal Drops
to Prevent 2019-
nCOV in Medical
Staff
Age 18 to 65 yrs, formally
serving as medical staff
in Taihe Hospital
2,944 2-arm, open-label to
IFN-a1b in a low-risk
group and IFN-a1b
and thymosin a1 in a
high-risk group
New COVID-19
diagnosis at
28 days
For an up-to-date listing of trials, search for “COVID-19” at the ClinicalTrials.gov website.
CT ¼ computed tomography; CXR ¼ chest x-ray; HFNC ¼ high flow nasal cannula; ICU ¼ intensive care unit; IFN ¼ interferon; rhIFN ¼ recombinant human interferon; WHO ¼ World Health Organization;
other abbreviations as in Tables 1 to 3.
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Results from a randomized, open-label study of 199
hospitalized adult patients with confirmed SARS-
CoV-2 infection assigned 1:1 to lopinavir 400 mg–
ritonavir 100 mg twice daily for 14 days with stan-
dard of care or standard of care alone were recently
published (48). All patients had an oxygen saturation
of 94% on room air or a ratio of partial pressure of
oxygen to the fraction of inspired oxygen <300
mg Hg. The primary endpoint was time to clinical
improvement, where clinical improvement was
defined based on an ordinal scale or survival from the
hospital. The study was designed for 80% power with
a 2-sided significance level of a of 0.05 to detect an 8-
day difference in median time to clinical improve-
ment. Here, the median time to clinical improvement
was 16.0 days (IQR: 13.0 to 17.0 days) in the lopinavir/
ritonavir group compared with 16.0 days (IQR: 15.0 to
18.0 days) with standard care. The mortality at
28 days in the treatment group was similar to that
observed in the standard care group (19.2% vs. 25%;
difference: 5.8%; 95% CI: 17.3% to 5.7%), as was
the detectable viral load. However, there were some
suggestions of potential benefit with lopinavir/rito-
navir with a shorter intensive care unit stay (median:
6 days vs. 11 days) and a shorter time to hospital
discharge (median: 12 days vs. 14 days). As noted, the
fixed-dose combination of lopinavir/ritonavir is 1
treatment arm in the SOLIDARITY trial (Table 3) (40).
IMMUNOMODULATORY THERAPIES. Interferons (IFNs)
are cytokines that activate the innate immune system
in response to viral infection. Type I interferons (IFN-
a/b) are synthesized by most cell types in the body
response to a viral infection, whereas type II inter-
feron (IFN-g) is produced by immune cells following
antigen stimulation. Both type I and type II IFNs
provoke the synthesis of proteins that have antiviral
and immunomodulatory effects. Recombinant IFN-b
has been shown to inhibit SARS-CoV replication
in vitro more effectively than either IFN-a or IFN-g
TABLE 5 Select Treatment Trials With Multiple Targets
Drug Name
Mechanism
of Action NCT Number Title
Lopinavir þ ritonavir; ribavirin; IFN-b1b Antiretroviral and immunomodulatory NCT04276688 Lopinavir/Ritonavir, Ribavirin and IFN-beta Combination
for nCoV Treatment
Lopinavir þ ritonavir; hydroxychloroquine Antiretroviral and viral entry NCT04307693 Comparison of Lopinavir/Ritonavir or Hydroxychloroquine
in Patients With Mild Coronavirus Disease (COVID-19)
Remdesivir þ hydroxychloroquine;
remdesivir; hydroxychloroquine
Antiretroviral and viral entry NCT04321616 Efficacy of Different Anti-viral Drugs in COVID-19 Infected
Patients
Combinations of oseltamivir, chloroquine,
darunavir, ritonavir, lopinavir, oseltamivir,
favipiravir
Antiretroviral and viral entry NCT04303299 Various Combination of Protease Inhibitors, Oseltamivir,
Favipiravir, and Hydroxychloroquine for Treatment
of COVID19: A Randomized Control Trial (THDMS-
COVID-19)
Favipiravir; chloroquine phosphate Antiretroviral and viral entry NCT04319900 Clinical Trial of Favipiravir Tablets Combined With
Chloroquine Phosphate in the Treatment of Novel
Coronavirus Pneumonia
Remdesivir; lopinavir þ ritonavir; IFN-b1a;
hydroxychloroquine
Antiretroviral, viral entry, and
immunomodulatory
NCT04315948 Trial of Treatments for COVID-19 in Hospitalized Adults
(DisCoVeRy)
Favipiravir þ tocilizumab Antiretroviral and immunomodulatory NCT04310228 Favipiravir Combined With Tocilizumab in the Treatment of
Corona Virus Disease 2019
For an up-to-date listing of trials, search for “COVID-19” at the ClinicalTrials.gov website.
IL ¼ interleukin; other abbreviations as in Tables 1 to 4.
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(49,50). Interestingly, IFN-g down-regulates the
expression of ACE2 on the cell surface and protects
type I pneumocytes from SARS-CoV infection (51).
The combination of lopinavir/ritonavir and IFN-b1b is
being evaluated in the treatment of laboratory-
confirmed MERS requiring hospitalization (52) and
will also be evaluated in the SOLIDARITY trial (40).
A number of additional immunomodulatory agents
are also currently being evaluated, including the
interleukin (IL)-6 inhibitor, tocilizumab, and gluco-
corticosteroids (Tables 4 and 5), given the cytokine
storm syndrome that has been observed in subgroups
with severe COVID-19 (53) with increased levels of
IL-2, IL-6, IL-7, and additional inflammatory cyto-
kines (54). One meta-analysis suggested that the
mean IL-6 levels were 2.9-fold (95% CI: 1.17 to 7.19-
fold) greater in patients with complicated compared
with noncomplicated COVID-19 (54). Tocilizumab
(Actemra, Genentech) is FDA-approved for the
treatment of severe cytokine release syndrome in
patients treated with chimeric antigen receptor T-cell
therapy and is also approved for the treatment of
rheumatoid arthritis (55–58). Tocilizumab is a mono-
clonal antibody that binds the IL-6 receptor, both the
membrane-bound and soluble forms, thus inhibiting
both classic and trans-IL-6 downstream signaling.
Similarly, the IL-6 humanized murine chimeric
monoclonal antibody siltuximab, although not FDA-
approved for the treatment of cytokine release syn-
drome, has also been used in the treatment of cyto-
kine release syndrome and is also being studied as a
potential therapy in severe COVID-19 infections. Sil-
tuximab (Sylvant, Janssen Biotech Inc., Horsham,
Pennsylvania) binds directly to IL-6 and prevents the
activation of immune effector cells. Sarilumab (Kev-
zara, Sanofi US, Bridgewater, New Jersey) is a human
monoclonal antibody against the IL-6 receptor that
was developed for the treatment of rheumatoid
TABLE 5 Continued
Study Population
Targeted
Enrollment Study Design Primary Outcome Measure
Age $18 yrs hospitalized for virologically
confirmed 2019-nCoV infection with NEWS$1
on recruitment; febrile with symptoms and
duration of symptoms #10 days
127 Randomized, open-label (1:1:1) to lopinavir þ
ritonavir; or ribavirin; or IFN-b1b
Time to negative nasopharyngeal viral RT-PCR
assessed up to 1 month
Age 16–99 yrs with confirmed mild COVID-19
(NEWS 0–4)
150 Randomized, open-label (1:1:1) lopinavir þ ritonavir;
or hydroxychloroquine; or standard care
Viral load at hospital days 3, 5, 7, 10, 14, 18
Age $18 yrs with confirmed SARS-CoV-2 by
RT-PCR, admitted to hospital or ICU
700 Randomized, Open-Label (1:1:1) remdesivir; or
hydroxychloroquine; or remdesivir þ
hydroxychloroquine adaptive controlled design;
comparison with standard of care
In-hospital mortality at 3 weeks
Age 16–100 yrs with COVID-19 diagnosis 320 Randomized, open-label, oseltamivir þ chloroquine;
or darunavir þ ritonavir þ oseltamivir; or
lopinavir þ ritonavir þ oseltamivir; or
favipiravir þ lopinavir þ ritonavir; or darunavir þ
ritonavir þ oseltamivir þ chloroquine; or
darunavir þ ritonavir þ favipiravir þ chloroquine
Time to negative detection of SARS-CoV-2 in
nasopharyngeal swab at 24 weeks
Age 18–75 yrs; diagnosed with nCoV pneumonia
with a course of illness no more than 14 days;
if the course is >14 days, no progression by
chest radiograph within 7 days; respiratory
symptoms; positive COVID-19 RT-PCR within
3 days
150 Randomized, double-blind 3-arm study of
favipiravir þ chloroquine; or favipiravir; or
placebo
Time to improvement of respiratory symptoms
Number of days of viral shedding
Frequency of improvement of respiratory
symptoms
Age $18 yrs, laboratory-confirmed SARS-CoV-2
infection as determined by RT-PCR or other
assay <72 h prior to randomization,
hospitalized patients with illness of any
duration, and pulmonary exam abnormalities
and pulse O2 # 94%, requiring O2, or
requiring mechanical ventilation, or acute
respiratory failure requiring mechanical
ventilation and/or supplemental O2
3,100 Adaptive, randomized, open-label 1:1:1:1:1 to
remdesivir; or lopinavir/ritonavir; or lopinavir/
ritonavir þ INF-b1a; or hydroxychloroquine; or
standard of care
Percentage of subjects reporting disease severity
on a 7-point ordinal clinical scale reflective of
hospitalization and oxygenation status; or
death at 15 days
Age 18–65 yrs, COVID-19 diagnosis,
increased IL-6
150 Randomized, open-label (1:1:1) of favipiravir þ
tocilizumab; or favipiravir; or tocilizumab
Clinical cure rate at 3 months
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arthritis that is also being evaluated for severe
COVID-19.
There are no systematically obtained clinical data
yet that support a benefit to the use of steroids, and
some reports have suggested a possible detriment
with delayed viral clearance and increased risk of
infection with MERS and SARS, although the role of
steroids in COVID-19 is an area of active investigation
(Table 4) (59).
COVID-19 AND CARDIOVASCULAR DISEASE
The COVID-19 pandemic has presented innumerable
challenges to health care organizations and health
care providers. Given that the vast majority of pa-
tients with cardiovascular disease are at high risk
for SARS-CoV-2 infection, the cardiovascular and
cardio-oncology communities will play a major
role in caring for patients with COVID-19 now and for
the foreseeable future. As a community, we have a
long tradition of enrolling patients into clinical
trials that evaluate therapeutic agents whose
mechanisms of action are familiar, which facilitates
reaching clinical equipoise when enrolling patients
in clinical trials. In the coming months, our com-
munities will be asked to contribute patients to
clinical trials where the mechanisms of action of the
therapeutic agents are less familiar and the
FIGURE 1 Interaction of CoVs With the RAS
Angiotensin-converting enzyme (ACE) converts angiotensin I (ANG1) (angiotensin 1-10) to angiotensin II (ANG2) (angiotensin 1-8), which is
the major effector peptide of the renin-angiotensin system (RAS). ANG2 mediates its effects through selective interactions with G-protein–
coupled angiotensin II type 1 receptor (AT1R) and G-protein–coupled angiotensin II type 1 type 2 receptor (AT2R). ANG2 is degraded to
ANG-(1-7) by angiotensin-converting enzyme 2 (ACE2), ANG-(1-7) binds to the Mas receptor (not shown). The ACE2–ANG-(1-7)–Mas receptor
axis opposes the effects of ACE–ANG2–AT1 axis. The binding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike
protein to ACE2 induces ACE2 shedding by activating a disintegrin and metalloproteinase-17 (ADAM-17). A decrease in ACE2 levels would be
expected to result in a decrease in the levels ANG-(1-7) levels (cytoprotective) and a corresponding increase in tissue levels of ANG2
(proinflammatory and profibrotic). Transmembrane serine protease 2 (TMPRSS2), a type II cell membrane serine protease that activates the
spike protein of SARS-CoV-2 and allows it to bind to ACE2. Modified from Simmons et al. (25). CoVs ¼ coronaviruses; P ¼ phosphorylation.
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knowledge base required for providing care for
COVID-19 is accelerating at a dizzying pace. Here we
have tried to provide a foundation for physicians
who are on the front line of providing care to pa-
tients with COVID-19, so that they can better
understand the emerging cardiovascular epidemi-
ology of COVID-19, as well as the biological
rationale for the plethora of clinical trials that are
either being designed or are currently recruiting
patients.
FIGURE 2 The Replication Strategy of SARS-CoV
(a) The severe acute respiratory syndrome coronavirus (SARS-CoV) spike (S) glycoprotein attaches to the angiotensin-converting enzyme 2
(ACE2) receptor on the cell surface. On entering the cytoplasm, the viral core particle, which contains the positive (50 to 30) strand genomic
ribonucleic acid (RNA), is released into the cytoplasm of the cell (b). The positive-strand viral RNA is translated on host ribosomes to generate
a large polyprotein (c) that undergoes proteolytic processing to generate multiple viral proteins, including an RNA-dependent RNA poly-
merase (RdRp). The RNA-dependent RNA polymerase generates a full-length, antisense negative-strand (30 to 50) viral RNA strand (d) that
serves as template for replicating positive-strand viral genomic RNA, as well as shorter negative-strand RNAs (e) that serve as templates for
synthesizing messenger ribonucleic acids (mRNAs) that code for structural proteins of the virus (f), including the S, membrane (M), envelope
(E), and nucleocapsid (N) proteins. Translation of viral mRNAs occurs using the host endoplasmic reticulum (ER) (g). Once the viral structural
proteins, S, E, and M, are translated and inserted into the ER, they move along the secretory pathway to the endoplasmic reticulum-Golgi
intermediate compartment (ERGIC) (h). The viral proteins become encapsulated and bud into membranes containing viral structural proteins,
where mature virions are assembled. (i) Following assembly, virions are transported to the cell surface in vesicles and released by exocytosis.
Modified from Turner et al. (43). ORF ¼ open reading frame.
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